Randomized Trial of a Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors

What this Trial Is About

Researchers are evaluating a digital health intervention called PROMOTE to support lung cancer survivors undergoing treatment aimed at cure. The study focuses on people with stages I-III non-small cell lung cancer receiving chemotherapy with curative intent. It aims to improve physical function, manage breathlessness and sleep problems, increase physical activity, encourage healthy eating, and enhance overall wellbeing. The trial compares PROMOTE to enhanced usual care, including educational materials, to see which better supports survivors' health and quality of life. Participants will be randomly assigned to one of two groups: one receives the PROMOTE app delivered on a tablet, which includes educational modules and behavioral strategies for managing symptoms and improving lifestyle; the other group receives standard oncology care plus health education materials from the American Cancer Society. The intervention lasts about 10 to 12 weeks, during which participants use the app at their own pace alongside usual cancer treatment. Throughout the study, participants complete surveys at enrollment and at 6, 12, and 24 weeks to track changes in physical function, breathing difficulties, sleep disturbance, physical activity, diet, mood, and quality of life. The study also monitors participants' confidence in managing their health and coping skills. After 24 weeks, those in the control group will have the option to access the PROMOTE app. The total participation time spans about 24 weeks from enrollment to final assessment.

A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors